Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 11/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 5/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213393 | 0.86 | MAPT (0.46) | MAPTSMN1; SMN2 | |
| SCHEMBL215285 | 0.83 | LTA4H (0.46) | SMN1; SMN2 | |
| SCHEMBL214316 | 0.83 | BTK (0.42) | EPHX2 | |
| SCHEMBL217226 | 0.82 | MEN1 (0.48) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL214778 | 0.82 | CHEK2 (0.47) | MAPTKITFLT3 | |
| SCHEMBL214714 | 0.81 | MAPT (0.44) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL215754 | 0.80 | KDM1A (0.42) | MAPTTP53 | |
| SCHEMBL214139 | 0.80 | MAPT (0.49) | MAPTTP53SMN1; SMN2MAPK14SMO | |
| Hydrochloric Acid SCHEMBL213648 | 0.80 | KDM1A (0.42) | MAPTTP53 | |
| SCHEMBL217126 | 0.79 | MAPT (0.41) | MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | MAPT 2138/4885TP53 1743/4885SMN1; SMN2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.